000042886 001__ 42886
000042886 005__ 20240506124407.0
000042886 0247_ $$2doi$$a10.6083/bpxhc42886
000042886 037__ $$aETD
000042886 041__ $$aeng
000042886 245__ $$aClathrin mediated endocytosis in Alzheimer's Disease: using biomarkers to uncover disease mechanism
000042886 260__ $$bOregon Health and Science University
000042886 269__ $$a2023-11-28
000042886 336__ $$aDissertation
000042886 502__ $$bPh.D.
000042886 502__ $$gNeuroscience
000042886 520__ $$aClathrin mediated endocytosis (CME) is emerging as a critical player in the development and progression of AD in multiple brain cell types. CME is an important intersection between early neuronal dysfunction via Aβ1-42 accumulation and downstream effects that contribute to neuronal viability, such as synaptic vesicle recycling deficits and disruption of AMPAR regulation. Not only is Aβ1-42 produced following CME of APP, but internalization of multiple forms of extracellular Aβ1-42 contribute to downstream neuronal pathology. In astrocytes and microglia, which are heavily involved in clearance of extracellular Aβ1-42 in the brain, CME disruptions reduce internalization of Aβ1-42. Ultimately, CME appears to be involved in dysfunction in multiple cell types across early and late stages of AD. Thus, elucidating the mechanisms of CME and how their disruption is related to AD pathogenesis or neuroprotection in each brain cell type would both lead to a better understanding of AD mechanisms and potentially point to novel targets for the treatment or prevention of AD. In this dissertation work, I have begun to assess CME in the context of AD, using human post-mortem samples and the 5xFAD AD mouse model.
000042886 536__ $$oNIH$$cR36AG073792
000042886 540__ $$fCC BY
000042886 542__ $$fIn copyright - single owner
000042886 650__ $$aAlzheimer Disease$$014513
000042886 650__ $$aModels, Animal$$033025
000042886 650__ $$aClathrin$$016769
000042886 650__ $$aEndocytosis$$018417
000042886 6531_ $$aclathrin mediated endocytosis
000042886 6531_ $$aintersectin 1
000042886 691__ $$aSchool of Medicine$$041369
000042886 692__ $$aDepartment of Anesthesiology and Perioperative Medicine$$041393
000042886 7001_ $$aSmith, Sierra Jaye$$uOregon Health and Science University$$041354$$10000-0003-4130-5831
000042886 7201_ $$aSaugstad, Julie$$uOregon Health and Science University$$041354$$10000-0002-2996-9611$$eAcademic advisor$$7Personal
000042886 7201_ $$aSandau, Ursula$$uOregon Health and Science University$$041354$$10000-0002-3646-7089$$eCo-Mentor$$7Personal
000042886 7201_ $$aCopenhaver, Philip$$uOregon Health and Science University$$041354$$10000-0003-0918-3264$$eCommittee chair$$7Personal
000042886 7201_ $$aMonk, Kelly$$uOregon Health and Science University$$041354$$10000-0003-1803-3495$$eCommittee member$$7Personal
000042886 7201_ $$aMishra, Anusha$$uOregon Health and Science University$$041354$$10000-0002-3642-5049$$eCommittee member$$7Personal
000042886 7201_ $$aBaltan, Selva$$uOregon Health and Science University$$041354$$10000-0003-1123-3582$$eCommittee member$$7Personal
000042886 789__ $$eIs original form of$$w10.3389/fnagi.2024.1378576$$2DOI
000042886 792__ $$aJaye S, Sandau US, Saugstad JA. Clathrin mediated endocytosis in Alzheimer's disease: cell type specific involvement in amyloid beta pathology. Front Aging Neurosci. 2024 Apr 17;16:1378576. doi: 10.3389/fnagi.2024.1378576. PMID: 38694257; PMCID: PMC11061891.
000042886 8564_ $$94bdce44c-d767-4dec-8351-6081351a3fb5$$s4678231$$uhttps://digitalcollections.ohsu.edu/record/42886/files/Smith.Sierra.2024.pdf
000042886 909CO $$ooai:digitalcollections.ohsu.edu:42886$$pstudent-work
000042886 980__ $$aTheses and Dissertations
000042886 981__ $$aPublished$$b2024-05-06